Sibold William John
Transaction: 07/20/2026
SELL
Change
-280
Price
$555.05
Filing
07/20/2026
Type
SELL
Madrigal Pharmaceuticals, Inc.
MDGL • Biotechnology
$541.08
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$15.77B
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 404.5%Manageable debt level · 0.59Healthy liquidity · 4.01Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$541.08
Change0.00%
Shares Out29.15M
Market Cap$15.77B
Enterprise Value$15.27B
52W Range298.00 - 615.00
Beta-1.06
P/E-48.51
P/S12.28
P/B30.11
P/FCF-75.35
EV/Sales11.90
Price$541.08
Change0.00%
Shares Out29.15M
Market Cap$15.77B
Enterprise Value$15.27B
52W Range298.00 - 615.00
Beta-1.06
P/E-48.51
P/S12.28
P/B30.11
P/FCF-75.35
EV/Sales11.90
EV/EBITDA-50.03
EV/FCF-72.98
Earnings Yield-2.06%
FCF Yield-1.33%
Dividend Yield0.00%
Gross Margin94.14%
Oper. Margin-31.31%
Profit Margin-30.08%
Debt/Eq0.59
Current Ratio4.01
Quick Ratio3.77
Target$677.00
Target Upside25.12%
Target Median$649.00
Target Range542.00 - 962.00
Volume1.49M
Avg Volume333.59K
EPS Surprise0.36
Investment DNA
How strong this company looks for long-term investors
42
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
73/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Positive revenue growth · 404.5%Manageable debt level · 0.59Healthy liquidity · 4.01Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 25 analyst votes · 2026-09-04
92/100
Bullish
Bullish
22
Hold
2
Bearish
1
Price Target
2026-07-31
Low
$542.00
Mean
$634.40
Median
$649.00
High
$709.00
Insider Transactions
Recent executive and insider activity
Sibold William John
Transaction: 07/17/2026
SELL
Change
-50,000
Price
Not reported
Filing
07/20/2026
Type
SELL
Sibold William John
Transaction: 07/17/2026
BUY
Change
+50,000
Price
Not reported
Filing
07/20/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Sibold William John | SELL | -280 | $555.05 | 07/20/2026 | 07/20/2026 |
| Sibold William John | SELL | -50,000 | Not reported | 07/17/2026 | 07/20/2026 |
| Sibold William John | BUY | +50,000 | Not reported | 07/17/2026 | 07/20/2026 |
| BAKER BROS. ADVISORS LP | BUY | +1,532 | $499.86 | 06/17/2026 | 06/18/2026 |
| BAKER BROS. ADVISORS LP | BUY | +908 | Not reported | 06/17/2026 | 06/18/2026 |
| Brennan Daniel J. | BUY | +681 | $499.86 | 06/17/2026 | 06/18/2026 |
| Brennan Daniel J. | BUY | +404 | Not reported | 06/17/2026 | 06/18/2026 |
| Daly James M | BUY | +766 | $499.86 | 06/17/2026 | 06/18/2026 |
| Daly James M | BUY | +454 | Not reported | 06/17/2026 | 06/18/2026 |
| FOUSE JACQUALYN A | BUY | +766 | $499.86 | 06/17/2026 | 06/18/2026 |
| FOUSE JACQUALYN A | BUY | +454 | Not reported | 06/17/2026 | 06/18/2026 |
| Levy Richard S | BUY | +766 | $499.86 | 06/17/2026 | 06/18/2026 |
| Levy Richard S | BUY | +454 | Not reported | 06/17/2026 | 06/18/2026 |
| Taub Rebecca | BUY | +766 | $499.86 | 06/17/2026 | 06/18/2026 |
| Taub Rebecca | BUY | +454 | Not reported | 06/17/2026 | 06/18/2026 |
| Soergel David | SELL | -1,042 | $495.74 | 06/01/2026 | 06/01/2026 |
| Levy Richard S | SELL | -80 | $519.98 | 05/22/2026 | 05/22/2026 |
| Soergel David | SELL | -844 | $515.90 | 05/18/2026 | 05/18/2026 |
| Taub Rebecca | SELL | -491 | $431.94 | 03/06/2026 | 03/06/2026 |
| Huntsman Carole | SELL | -419 | $431.94 | 03/06/2026 | 03/06/2026 |